A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Inclusion Criteria:

- Relapsed or refractory (R/R) multiple myeloma (MM) with documented evidence of
progression during or after the subject's last treatment regimen.

- Measurable disease as described in the protocol.

- Received at least 1 prior line of therapy, as described in the protocol.

- Must meet prior antimyeloma treatment parameters, as described in the protocol, and
includes:

- Received at least 2 consecutive cycles of lenalidomide or a lenalidomide containing
regimen

- Refractory to lenalidomide

- Exposed to a proteasome inhibitor (PI) alone or in combination with another agent.

- Had a response of partial response (PR) or better to prior therapy based on the
investigator's determination of response as defined by International Myeloma Working
Group (IMWG) criteria.

- Has t(11;14) status as described in the protocol and meets the following criteria:

- For Part 1: MM subjects independent of cytogenetic profile.

- For Part 2, Arm A: subject must be t(11;14) positive.

- For Part 2, Arm B: subject must be t(11;14) negative.

- An Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.

- Adequate kidney, liver and hematologic laboratory values.

Exclusion Criteria:

- Previous treatment with venetoclax or other BCL-2 inhibitors, or previous treatment
with pomalidomide

- Known sensitivity to any IMiDs

- Allogenic or syngeneic stem cell transplant within 6 months before the first dose of
study drug or active ongoing graft versus host disease

- Autologous stem cell transplant within 12 weeks before the first dose of study drug

- Known meningeal involvement of MM